ArticleInternational journal of clinical pharmacy2025

Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe.

Yuyang Sun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.